Modulation of the chemotactic properties of complement fragments C5a and C3 by the anti-inflammatory agent, SC-41930 D. J. FretlandD. L. WidomskiT. S. Gaginella Inflammatory Cells Pages: 5 - 7
Neutrophil collagenase activation: The role of oxidants and cathepsin G C. CapodiciR. A. Berg Inflammatory Cells Pages: 8 - 10
Macrophage-mediated killing of splenic lymphocytes in adjuvant-induced arthritis A. C. HanglowH. BachmannJ. W. Coffey Inflammatory Cells Pages: 11 - 15
Changes in inositol 1,4,5-trisphosphate mass in agonist-stimulated human neutrophils D. A. FrumanD. A. GamacheM. J. Ernest Inflammatory Cells Pages: 16 - 19
Role of corticosterone in modulation of eicosanoid biosynthesis and antiinflammatory activity by 5-lipoxygenase (5-LO) and cyclooxygenase (CO) inhibitors L. A. TomchekD. A. HartmanR. P. Carlson Inflammatory Cells Pages: 20 - 24
The effects of (R)-N-(1-methyl-2-phenylethyl) adenosine (L-PIA), a standard A1-selective adenosine agonist on rat acute models of inflammation and neutrophil function M. E. LeschM. A. FerinD. J. Schrier Inflammatory Cells Pages: 25 - 27
Contribution of the monocyte to thrombotic potential C. R. SpillertE. J. Lazaro Inflammatory Cells Pages: 28 - 29
Effects of the prostaglandin analogue misoprostol on inflammatory mediator release by human monocytes D. L. WidomskiR. E. WalshT. S. Gaginella Inflammatory Cells Pages: 30 - 31
Granulocyte-macrophage colony-stimulating factor (GM-CSF) primes human neutrophils for enhanced phosphatidylcholine breakdown by phospholipase D S. BourgoinP. BorgeatP. E. Poubelle Inflammatory Cells Pages: 32 - 34
Cytotoxicity of human phagocytes studiedin vitro in a novel model based on Neutral Red absorbtion R. BrattsandE. -L. DelanderE. Wieslander Inflammatory Cells Pages: 35 - 37
Crystal-neutrophil interactions lead to interleukin-1 synthesis C. J. RobergeJ. GrassiP. E. Poubelle Cytokines Pages: 38 - 41
Leukotriene B4 up-regulates IL-6 rather than IL-1 synthesis in human monocytes P. E. PoubelleJ. StankovaM. Rola-Pleszczynski Cytokines Pages: 42 - 45
Effects of indomethacin, triamcinolone, and dexamethasone on recombinant human interleukin-1-induced substance P and prostaglandin E2 levels in rabbit knee joints E. M. O'ByrneV. BlancuzziA. Y. Jeng Cytokines Pages: 46 - 48
Inhibition of interleukin-2 production and lymphocyte responsiveness by the cell activation inhibitor, CI-959 M. K. DongD. J. WilburnR. B. Gilbertsen Cytokines Pages: 53 - 55
Effects of anti-arthritic drugs on IL-1 induced inflammation in rats P. S. HrubeyA. K. HarveyS. Chandrasekhar Cytokines Pages: 56 - 59
Effects of IL-1 muteins on cartilage degradation and as inducers of acute inflammation M. A. PrattaE. C. ArnerW. Galbraith Cytokines Pages: 60 - 62
The effect of treatment with recombinant γ-interferon on adjuvant-induced arthritis in rats H. NakajimaH. TakamoriW. Tsukada Cytokines Pages: 63 - 65
Pharmacological modulation of rat monocytes:In vivo effects on Ia expression and interleukin-1 production E. J. SchenkelaarsH. N. SinghF. Quagliata PLA2/5-Lipoxygenase Pages: 66 - 69
AGN 190383, a novel phospholipase inhibitor with topical anti-inflammatory activity G. W. De VriesG. LeeL. A. Wheeler PLA2/5-Lipoxygenase Pages: 70 - 72
BI-L-239, a 5-lipoxygenase inhibitor, blocks inhaled antigen-induced airway hyperresponsiveness in conscious guinea pigs W. W. WolyniecA. M. LaPlanteC. D. Wegner PLA2/5-Lipoxygenase Pages: 73 - 76
Antiflammin-2 (HDMNKVLDL) does not inhibit phospholipase A2 activities W. C. HopeB. J. PatelD. R. Bolin PLA2/5-Lipoxygenase Pages: 77 - 80
Eicosanoid production and phospholipase A2 secretion by peritoneal macrophages from rats with adjuvant-induced arthritis C. E. T. BakC. M. AndersonD. W. Morgan PLA2/5-Lipoxygenase Pages: 81 - 83
Comparison of antiinflammatory and antiallergic drugs in the melittin- and D49 PLA2-induced mouse paw edema models D. A. HartmanL. A. TomchekR. P. Carlson PLA2/5-Lipoxygenase Pages: 84 - 88
PAF and LTB4 biosynthesis in the human neutrophil: Effects of putative inhibitors of phospholipase A2 and specific inhibitors of 5-lipoxygenase K. B. GlaserY. W. LockJ. Y. Chang PLA2/5-Lipoxygenase Pages: 89 - 92
Phospholipase A2 acyl-hydrolytic activity in rat RPAR-induced pleurisy J. W. BerkenkopfL. R. MarinariB. M. Weichman PLA2/5-Lipoxygenase Pages: 93 - 96
Characterization of phospholipase A2 activity in rat RPAR-induced pleurisy L. R. MarinariJ. W. BerkenkopfB. M. Weichman PLA2/5-Lipoxygenase Pages: 97 - 99
Anti-inflammatory effects of LY221068 and LY269415 J. A. PanettaD. N. BenslayP. P. K. Ho PLA2/5-Lipoxygenase Pages: 100 - 102
CoA-independent transacylase has characteristics distinct from those of PLA2 enzymes J. D. WinklerC. -M. SungL. Huang PLA2/5-Lipoxygenase Pages: 103 - 105
Phosphonate-phospholipid analogues inhibit human phospholipase A2 L. A. MarshallB. BologneseM. Gelb PLA2/5-Lipoxygenase Pages: 106 - 109
Methoxyalkyl thiazoles: A novel series of potent, orally active and enantioselective inhibitors of 5-lipoxygenase R. M. McMillanT. G. C. BirdS. J. Foster PLA2/5-Lipoxygenase Pages: 110 - 112
Phospholipase A2 (PLA2) activity in bovine pulmonary artery endothelial cells R. GoodmanT. M. StevensJ. S. Kerr PLA2/5-Lipoxygenase Pages: 113 - 116
Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole bloodex vivo P. SiroisP. BorgeatJ. Kesterson PLA2/5-Lipoxygenase Pages: 117 - 120
Are tolfenamic acid and tenidap dual inhibitors of 5-lipoxygenase and cyclo-oxygenase? K. E. ProudmanR. M. McMillan PLA2/5-Lipoxygenase Pages: 121 - 124
CGS 22745: A selective orally active inhibitor of 5-lipoxygenase E. KimbleT. KowalskiJ. Wasley Design and Development of Drugs Pages: 125 - 128
Relationship of blood markers to disease severity and drug efficacy in rat adjuvant arthritis J. R. DoughtyR. L. GoldbergG. Di Pasquale Design and Development of Drugs Pages: 129 - 131
Development of high-throughput radioligand binding assays for interleukin-1α (IL-1α) and tumor necrosis factor (TNF-α) in isolated membrane preparations B. L. MaloffR. E. Delmendo Design and Development of Drugs Pages: 132 - 134
Pharmacological properties of five diclofenac metabolites identified in human plasma I. Wiesenberg-BoettcherJ. PfeilschifterP. Wenk Design and Development of Drugs Pages: 135 - 137
New highly potent bradykinin B2 receptor antagonists D. RegoliN. -E. RhalebG. Drapeau Design and Development of Drugs Pages: 138 - 141
2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanamide (NPC 15437): A selective inhibitor of protein kinase C J. P. SullivanJ. R. ConnorR. M. Burch Design and Development of Drugs Pages: 142 - 144
Leukotriene biosynthesis inhibition by aryl and aroyl substituted naphthoquinones D. M. RolandW. M. MacchiaT. J. Kowalski Design and Development of Drugs Pages: 145 - 147
A synthetic mycobacterial heat shock peptide prevents adjuvant arthritis but not proteoglycan-induced synovitis in the rat H. W. GoldenC. A. ManigliaG. E. Ranges Autoimmunity Pages: 148 - 150
15-Deoxyspergualin (15-DOS) has a curative effect on the development of SLE-like autoimmune disease in MRL/1 mice H. U. SchorlemmerR. R. BartlettF. R. Seiler Autoimmunity Pages: 151 - 155
15-Deoxyspergualin (15-DOS) for therapy in an animal model of multiple sclerosis (MS): Disease modifying activity on acute and chronic relapsing experimental allergic encephalomyelitis (EAE) H. U. SchorlemmerF. R. Seiler Autoimmunity Pages: 156 - 160
Inhibitory effects of the anti-rat T-cell receptor (TCR) monoclonal antibody (MAb) R73 on various experimental autoimmune diseases H. U. SchorlemmerE. J. KanzyF. R. Seiler Autoimmunity Pages: 161 - 164
Corticosteroids and immunosuppressive agents in rabbit heterolamellar corneal transplant model E. OhiaP. Kulkarni Autoimmunity Pages: 165 - 168
IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis N. J. OlsenG. P. TealR. H. Brooks Autoimmunity Pages: 169 - 171
Effect of the leukotriene B4 receptor antagonist, SC-41930, on experimental allergic encephalomyelitis (EAE) in the guinea pig D. J. FretlandD. L. WidomskiT. S. Gaginella Non-Rheumatic Inflammatory Diseases Pages: 172 - 174
Histamine is a transient marker of small intestinal injury induced by luminal acetic acid and casein M. J. S. MillerX. -J. ZhangD. A. Clark Non-Rheumatic Inflammatory Diseases Pages: 175 - 177